Emily Greengard

400 total citations
19 papers, 297 citations indexed

About

Emily Greengard is a scholar working on Neurology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emily Greengard has authored 19 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Neurology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emily Greengard's work include Neuroblastoma Research and Treatments (8 papers), Cancer therapeutics and mechanisms (6 papers) and Lung Cancer Research Studies (2 papers). Emily Greengard is often cited by papers focused on Neuroblastoma Research and Treatments (8 papers), Cancer therapeutics and mechanisms (6 papers) and Lung Cancer Research Studies (2 papers). Emily Greengard collaborates with scholars based in United States, Italy and Canada. Emily Greengard's co-authors include Lynda E. Polgreen, Nathan Gossai, Brenda J. Weigel, Rochelle Bagatell, Arlene Naranjo, Antonella Borgatti, Daniel A. Saltzman, Steven G. DuBois, Michael S. Henson and Lance B. Augustin and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and European Journal of Cancer.

In The Last Decade

Emily Greengard

17 papers receiving 292 citations

Peers

Emily Greengard

ONCOL

NEURO

PRM

Anders R.L. Meyer United States

Bede van Schaijik New Zealand

Moses M. Kim United States

Lucile Delespaul France

Virginia Di Paolo Italy

Jonathan P. Giurintano United States

Kamal P. Sajwan United States

Д. М. Коновалов Russia

Valéry Attignon France

Luis M. Hernández France

Anders R.L. Meyer United States

Emily Greengard

61 ×0.5

325 ×3.2

ONCOL

44 ×0.5

NEURO

36 ×0.5

66 ×1.1

PRM

Citations per year, relative to Emily Greengard Emily Greengard (= 1×) peers Anders R.L. Meyer

Countries citing papers authored by Emily Greengard

Since Specialization

Citations

This map shows the geographic impact of Emily Greengard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Greengard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Greengard more than expected).

Fields of papers citing papers by Emily Greengard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Greengard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Greengard. The network helps show where Emily Greengard may publish in the future.

Co-authorship network of co-authors of Emily Greengard

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Greengard. A scholar is included among the top collaborators of Emily Greengard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Greengard. Emily Greengard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Greengard, Emily, et al.. (2025). Multifocal Kaposiform Hemangioendothelioma Successfully Treated With Sirolimus Monotherapy. Pediatric Dermatology. 43(1). 158–162.

Greengard, Emily, et al.. (2025). HeartWare™ HVAD support without anticoagulation. Indian Journal of Thoracic and Cardiovascular Surgery. 42(3). 377–380.

Greengard, Emily, Robin Williams, Branden S. Moriarity, et al.. (2024). A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood & Cancer. 71(6). e30938–e30938. 2 indexed citations

Naranjo, Arlene, Lena E. Winestone, Puja J. Umaretiya, et al.. (2023). Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.. Journal of Clinical Oncology. 41(16_suppl). 10010–10010. 5 indexed citations

Greengard, Emily, Noah Federman, Yanhong Zhou, et al.. (2023). Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).. Journal of Clinical Oncology. 41(16_suppl). TPS10068–TPS10068. 2 indexed citations

Eaton, Anne, et al.. (2021). CTIM-15. FIRST-IN-HUMAN PHASE 1 STUDY OF CD200 ACTIVATION RECEPTOR-LIGAND (CD200AR-L) AND ALLOGENEIC TUMOR LYSATE VACCINE IMMUNOTHERAPY FOR RECURRENT GLIOBLASTOMA: INITIAL RESULTS FROM AN ONGOING CLINICAL TRIAL. Neuro-Oncology. 23(Supplement_6). vi52–vi53. 2 indexed citations

Lee, Adam M., et al.. (2021). Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma. International Journal of Molecular Sciences. 22(20). 11168–11168. 23 indexed citations

Zhou, Xiaofei, Diane R. Mould, Ying Yuan, et al.. (2021). Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. The Journal of Clinical Pharmacology. 62(2). 206–219. 7 indexed citations

Greengard, Emily, Yaël P. Mossé, Xiaowei Liu, et al.. (2020). Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemotherapy and Pharmacology. 86(6). 829–840. 18 indexed citations

10.

Basile, Patrick, Emily Greengard, Brenda J. Weigel, & Logan G. Spector. (2020). Prognostic Factors for Development of Subsequent Metastases in Localized Osteosarcoma: A Systematic Review and Identification of Literature Gaps. Sarcoma. 2020. 1–7. 13 indexed citations

11.

Pinto, Navin, Arlene Naranjo, Emily Hibbitts, et al.. (2019). Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). European Journal of Cancer. 112. 66–79. 46 indexed citations

12.

Greengard, Emily, Xiaowei Liu, Olga Militano, et al.. (2019). A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).. Journal of Clinical Oncology. 37(15_suppl). e21519–e21519. 3 indexed citations

13.

Liszewski, Walter, Sheilagh Maguiness, Emily Greengard, & Christina Boull. (2018). The incidence of pediatric malignant soft tissue tumors of the skin and subcutaneous tissue. Pediatric Dermatology. 35(6). e427–e429. 3 indexed citations

14.

Greengard, Emily. (2018). Molecularly Targeted Therapy for Neuroblastoma. Children. 5(10). 142–142. 42 indexed citations

15.

Henson, Michael S., Emily Greengard, Antonella Borgatti, et al.. (2016). A phase I clinical study to evaluate safety of orally administered, genetically engineeredSalmonella entericaserovarTyphimuriumfor canine osteosarcoma. Veterinary Medicine and Science. 2(3). 179–190. 54 indexed citations

16.

Gossai, Nathan, et al.. (2015). Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatric Blood & Cancer. 62(6). 1078–1080. 67 indexed citations

17.

Greengard, Emily & Julie R. Park. (2015). ALK-Related Neuroblastic Tumor Susceptibility. 2 indexed citations

18.

Greengard, Emily, Yaël P. Mossé, Xiaowei Liu, et al.. (2015). Safety and tolerability of crizotinib in combination with chemotherapy for relapsed or refractory solid tumors or anaplastic large cell lymphoma: a Children’s Oncology Group phase I consortium study.. Journal of Clinical Oncology. 33(15_suppl). 10058–10058. 5 indexed citations

19.

Greengard, Emily, Christine E. Hill‐Kayser, & Rochelle Bagatell. (2013). Treatment of high-risk neuroblastoma in children: recent clinic trial results. Clinical Investigation. 3(11). 1071–1081. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact